OR WAIT null SECS
April 02, 2012
Contract API manufacturers and fine-chemical producers roll out capacity and service expansions.
February 02, 2012
As biopharmaceutical development and commercialization increases, companies are expanding their cold-chain capabilities.
January 02, 2012
Some recent advances involve strategies for accelerating reaction discovery, approaches for inducing chirality and stereochemical analysis, and applications in nanotechnology for protein elucidation.
Nanosized systems are important in drug delivery. Such nanosized systems include liposomes, nanocrystals, micelles, colloidal particles, quantum dots, and dendrimers. Dendrimers are class of synthetic macromolecules with highly branched, monodispersed, circular, and symmetrical architecture that are used as carrier molecules in drug delivery.
December 02, 2011
Expansion activity was limited as fine-chemical producers and CMOs of API and intermediates grapple with changing industry fundamentals.
November 02, 2011
Researchers develop various catalytic approaches for improving yield, purity, stereoselectivity, and process conditions.
September 02, 2011
Biocatalysis, chemocatalysis, and other chiral technologies continue to attract the investment dollars of CMOs and fine-chemical companies.
September 01, 2011
Direct dosing APIs during R&D studies can reduce the overall testing time of a drug candidate by allowing for a greater throughput of compounds through the R&D department.
The increasing cost of crucial manufacturing input factors, such as energy and raw materials, has been a severe threat to several companies.
As contract manufacturers and fine-chemical suppliers gather for CPhI/ICSE, effective strategies for technology differentiation are key in an increasingly competitive environment.